AthleticsMD Clinical Desk

Trending now

All trending →
In the news

New project receives $2.3 million to develop a database and AI model to identify therapeutic peptides

News-Medical reports that a University of Toronto team led by Joseph Brown has received $2.3 million USD from the Google.org Impact Challenge to build OpenPep, a proposed open-access database and AI model for predicting which peptides bind target proteins. The project is at an early stage: the team plans to produce up to 500 disease-relevant proteins and test peptide libraries against them.

news-medical.net · October 14, 2026

Our summary →
In the news

Weight loss drugs may protect against heart failure

Medical Xpress reports a Cedars-Sinai laboratory study, published in the European Heart Journal, in which low-dose semaglutide was given to rats and minipigs modelling obesity-associated heart failure with preserved ejection fraction. The drug did not reduce body weight but reduced heart stiffness, enlargement and scarring, and cleared fat around the heart and liver. Findings are in animals; researchers say they support studying GLP-1 drugs for heart failure.

medicalxpress.com · October 14, 2026

Our summary →
In the news

Oral IL-23 Inhibitor Shows Long-Term Safety, Efficacy in UC

Medscape reports long-term extension results from the phase 2b ANTHEM-UC trial, presented at ACG 2026, of once-daily oral icotrokinra, an IL-23 inhibitor, in moderate-to-severe ulcerative colitis. Of 136 patients who had responded by week 28 and entered the extension, 85% stayed on treatment through week 76. Clinical remission ranged from 56.3% to 59.1% across doses. No new safety signals were reported. Johnson & Johnson funded the study.

medscape.com · October 14, 2026

Our summary →
In the news

Semaglutide’s CV benefits may be related to more than weight loss

Healio reports on an analysis of SELECT trial data, published in the European Heart Journal, covering 17,604 adults with overweight or obesity but no diabetes. Researchers reported that weight loss and other measured risk factors could not fully explain the cardiovascular benefit of semaglutide 2.4 mg versus placebo, with wide confidence intervals. A Cleveland Clinic physician called the findings hypothesis-generating and said weight loss is likely still predominant.

healio.com · October 14, 2026

Our summary →

Latest

Browse by subject

All subjects →
SubjectWhat it coversLatestArticles
GLP-1 medicines and medical weight lossArticles on semaglutide, tirzepatide and other GLP-1 medicines: cost, coverage, evidence and what a supervised program involves.Semaglutide trial for addiction will track justice, jobs and housing outcomes15
Metabolic healthArticles on insulin resistance, prediabetes, thyroid, sleep, stress and nutrition, and what the research says about each.Nutrition before Crohn's disease surgery: what the 2024 AGA expert guidance advises1
Hormone therapyArticles on testosterone therapy, menopause hormone therapy and how hormone treatment is evaluated and monitored.Coming up: Menopause hormone therapy: what current evidence says0
IV therapy and hydrationArticles on intravenous hydration and vitamin infusions: what is in them, the evidence, and who they suit.Coming up: IV hydration: what the evidence supports0
Prehab, surgery and recoveryArticles on preparing for surgery, rehabilitation and recovering strength, from the research and the clinic.Prehab before major surgery: where five evidence sources agree, conflict and fall short14
Visits and everyday careArticles on same-day visits, referrals and what to bring to an appointment at a Maryland clinic.Coming up: Medical weight loss in Columbia and Laurel, Maryland: what a first visit covers0

GLP-1 medicines and medical weight loss

More →

Metabolic health

More →
Coming up

Protein needs while losing weight

On the publishing plan for the weeks ahead

Coming up

Thyroid testing: what it can and can't explain

On the publishing plan for the weeks ahead

Coming up

Sleep, weight and metabolism

On the publishing plan for the weeks ahead

Hormone therapy

More →
In the news

New research links postmenopausal ovarian tissue remodeling to elevated cancer vulnerability

News-Medical reports on a small study of ovaries from 28 postmenopausal women aged 50 to 75, by Northwestern University and the Buck Institute, in Aging Cell. Analysing 5,812 protein groups in normal tissue, researchers found older ovaries showed more inflammation- and remodeling-linked proteins, and some proteins previously tied to ovarian cancer were more abundant. The tissue was cancer-free. The researchers say whether ovaries should be removed remains unanswered.

news-medical.net · October 14, 2026

Our summary →
In the news

Ovaries remain active decades after menopause, study reveals

Medical Xpress reports a small study from Northwestern University and the Buck Institute, published in Aging Cell, that analysed 5,812 groups of proteins in normal ovarian tissue from 28 postmenopausal women ages 50 to 75. Older ovaries showed more inflammation- and remodeling-related proteins, and some proteins previously linked to ovarian cancer were more abundant, though all tissue appeared cancer-free. Researchers say whether these changes help or harm remains unknown.

medicalxpress.com · October 14, 2026

Our summary →
In the news

What doctors want women to know about menopause and heart health

Medical Xpress carries an American Heart Association awareness piece, with The Menopause Society, for Menopause Awareness Month. It notes menopause does not cause cardiovascular disease, but risk factors often shift in midlife; approximately 90% of women have at least one heart risk factor by menopause. It cites a study of more than 83,000 women ages 50–79 estimating 1 in 4 may develop atrial fibrillation after menopause.

medicalxpress.com · October 13, 2026

Our summary →

IV therapy and hydration

More →
Coming up

IV hydration: what the evidence supports

On the publishing plan for the weeks ahead

Prehab, surgery and recovery

More →

Visits and everyday care

More →
Coming up

Medical weight loss in Columbia and Laurel, Maryland: what a first visit covers

On the publishing plan for the weeks ahead

Coming up

Same-day sick visits near Laurel and Fort Meade

On the publishing plan for the weeks ahead

Coming up

For primary care: when to refer for medical weight management

On the publishing plan for the weeks ahead

AthleticsMD

Schedule an evaluation

AthleticsMD in Columbia and Laurel/Fort Meade builds prehabilitation, rehabilitation and physician-guided weight-loss plans around your own history.